CD4 News and Research

RSS

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Researchers work to develop dual antigen COVID-19 vaccine candidate

A new study has been published on the medRxiv* preprint server, which focuses on the development of a dual-antigen COVID-19' T cell' vaccine. This vaccine is developed based on the expression of both S protein and nucleocapsid (N) protein of SARS-CoV-2, using a next-generation human adenovirus serotype 5 (Ad5) platform.

12 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Study offers localized treatment direction for a cause of Crohn's disease

People with Crohn's disease are typically treated with powerful anti-inflammatory medications that act throughout their body, not just in their digestive tract, creating the potential for unintended, and often serious, side effects.

7 Apr 2021

Is non-severe SARS-CoV-2 infection characterized by early T cell proliferation?

To date, little evidence has been documented regarding the immune responses after the onset of the symptoms or virus detection. Further, no cross-sectional studies have been conducted that define the time of infection. Thereby, no report is available that explains the relationship between the earliest immune responses to COVID-19 and temporal kinetics. New research deals with this research gap using blood transcriptomics, multiparameter flow cytometry, and T cell receptor (TCR) sequencing methods.

6 Apr 2021

Study suggests T-cells don't determine survival in severe COVID-19

In the study, which appeared on the pre-print server medRxiv, the team found that when the monkeys were reinfected, the T cell-depleted animals showed anamnestic immune responses, the enhanced reaction of the body's immune system to an antigen that is related to an antigen previously encountered.

6 Apr 2021

New approach to CAR T gene therapy yields efficient and longer-lasting response against HIV

A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule.

3 Apr 2021

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

Study of twins reveals differences in adaptive immunity towards SARS-CoV-2

Twins may look alike on the outside, but not so much on the inside. That's one takeaway from a new preprint study posted to the medRxiv server where Brazilian researchers observed different T-cell responses in two pairs of identical twins exposed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One twin who was reinfected with SARS-CoV-2 four months after had low recognition of CD4+ and CD8+ T-cell epitopes.

31 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Diabetes drug appears to exploit vulnerability of AIDS-causing retrovirus HIV

A team led by scientists at the UNC School of Medicine discovered an important vulnerability of the AIDS-causing retrovirus HIV, and has shown in preclinical experiments that a widely used diabetes drug, metformin, seems able to exploit this vulnerability.

29 Mar 2021

New study may shed light on inflammatory bowel disease

Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.

26 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

New guidelines outline key new actions to improve delivery of HIV testing, treatment and care

These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living with HIV who are being treated for tuberculosis.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

CD4 News and Research

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Researchers work to develop dual antigen COVID-19 vaccine candidate

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Study offers localized treatment direction for a cause of Crohn's disease

Is non-severe SARS-CoV-2 infection characterized by early T cell proliferation?

Study suggests T-cells don't determine survival in severe COVID-19

New approach to CAR T gene therapy yields efficient and longer-lasting response against HIV

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

Study of twins reveals differences in adaptive immunity towards SARS-CoV-2

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

Diabetes drug appears to exploit vulnerability of AIDS-causing retrovirus HIV

New study may shed light on inflammatory bowel disease

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

New guidelines outline key new actions to improve delivery of HIV testing, treatment and care

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News